US Pharma MarketingASCO: AstraZeneca's Imfinzi, Imjudo duo shines in earlier-stage liver cancer
AstraZeneca is polishing the case for its Imfinzi (durvalumab) and Imjudo (tremelimumab) combo in liver cancer with a new phase 3 readout from its Emerald trial program assessing the immunotherapy The company's Emerald-3 study showed a 30% reduction in the risk of disease progression or death among embolization-eligible liver cancer patients who used an Imfinzi and Imjudo regimen. Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report Awards Gala Trending Oncology Supply Chain AI and Machine Learning Awards Outsourcing Awards Innovation Awards Pharma Marketing Awards Resources…
The company's Emerald-3 study showed a 30% reduction in the risk of disease progression or death among embolization-eligible liver cancer patients who used an Imfinzi and Imjudo regimen.
Source: FiercePharma